Scripscan:Surya Pharmaceutical Ltd
cmp:108
Code:532516
Story:Having made a foray into the contract manufacturing space, Surya is now increasing its focus on the contract research area. The company is in advanced stage of negotiation with a British company for the development of a cost-effective process for a new molecule. Surya expects that partnering with the British company at this early stage of development will open up huge contract manufacturing orders for it, once the molecule gets commercialised.Also, with expansion of its API capacity, Surya is also entering the high-end therapeutic segments like anticancer.Surya has put up a new plant in the tax-haven state of Jammu. The Jammu plant has been constructed in line with the US Food and Drug Administration (US FDA) standards primarily to manufacture new APIs and sterile cephalosporins. Surya has now entered the highmargin injectable business.I expect the Jammu facility to contribute an incremental Rs100 crore to Surya's revenues in the present fiscal.The entry into higher-end products will also have a positive impact on the company's margins, resulting in a robust 50% CAGR in profits over the next three years.It is currently highly undervalued .At current prices, Surya offers a remarkable combination of strong growth at cheap valuations.One can buy the stock at dips for decent capital appreciation in the coming months.
Search This Blog(Over 800 companies covered in the blog).
Archives : Old artciles
Tuesday, November 3, 2009
Important Disclaimer&Privacy policy
This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: arunsharemarket@gmail.com
Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.
